Provided herein is a drug delivery system comprising: a. substrate; b. a plurality of components combined with the substrate to form the drug delivery system; wherein at least one components comprises a bioabsorbable polymer and at least one other component comprises one or more active agents; where
Provided herein is a drug delivery system comprising: a. substrate; b. a plurality of components combined with the substrate to form the drug delivery system; wherein at least one components comprises a bioabsorbable polymer and at least one other component comprises one or more active agents; wherein at least part of the active agent is in crystalline form.
대표청구항▼
1. A drug delivery system comprising a. a substrate; andb. a plurality of bioabsorbable polymer layers combined with said substrate; and at least one active agent combined with said substrate; wherein each of said plurality of bioabsorbable polymer layers comprises a separately sintered bioabsorbabl
1. A drug delivery system comprising a. a substrate; andb. a plurality of bioabsorbable polymer layers combined with said substrate; and at least one active agent combined with said substrate; wherein each of said plurality of bioabsorbable polymer layers comprises a separately sintered bioabsorbable polymer layer; wherein said at least one active agent is present in crystalline form on at least one region of an outer surface of said drug delivery system. 2. The drug delivery system of claim 1, wherein 50% or less of the total amount of said at least one active agent is released after 24 hours in vitro elution. 3. The drug delivery system of claim 2, wherein in vitro elution is carried out in a 1:1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37° C.; wherein the amount of active agent released is determined by measuring UV absorption. 4. The drug delivery system of claim 3, wherein UV absorption is detected at 278 nm by a diode array spectrometer. 5. The drug delivery system of claim 1, wherein between 25% and 45% of the total amount of said at least one active agent is released after 24 hours in vitro elution in a 1:1 spectroscopic grade ethanol/phosphate buffer saline at pH 7.4 and 37° C.; wherein the amount of said at least one active agent released is determined by measuring UV absorption at 278 nm by a diode array spectrometer. 6. The drug delivery system of claim 1, wherein said at least one active agent is at least 50% crystalline. 7. The drug delivery system of claim 1, wherein said at least one active agent is at least 90% crystalline. 8. The drug delivery system of claim 1, wherein said bioabsorbable polymer comprises a PLGA copolymer. 9. The drug delivery system of claim 1, wherein said bioabsorbable polymer comprises a first PLGA copolymer with a ratio of about 40:60 to about 60:40 and a second PLGA copolymer with a ratio of about 60:40 to about 90:10. 10. The drug delivery system of claim 1, wherein said bioabsorbable polymer comprises a first PLGA copolymer having a molecular weight of about 10 kD and a second polymer is a PLGA copolymer having a molecular weight of about 19 kD. 11. The drug delivery system of claim 1, wherein said bioabsorbable polymer is selected from the group PLGA, PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e-caprolactone) PDO, poly(dioxolane) PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid) and mixture thereof. 12. The drug delivery system of claim 1, wherein said substrate comprises a stent. 13. The drug delivery system of claim 12, wherein said stent is formed of stainless steel or cobalt alloy. 14. The drug delivery system of claim 12, wherein said stent has a thickness of from about 50% to about 90% of a total thickness of the drug delivery system. 15. The drug delivery system of claim 1, wherein said drug delivery system has a thickness of from about 20 μm to about 500 μm. 16. The drug delivery system of claim 1, wherein said stent has a thickness of from about 50 μm to about 80 μm. 17. The drug delivery system of claim 1, wherein said drug delivery system has an active agent content of from about 5 μg to about 500 μg. 18. The drug delivery system of claim 1, wherein said at least one active agent comprises a macrolide immunosuppressive (limus) drug. 19. The drug delivery system of claim 18, wherein said at least one active agent is rapamycin, a prodrug, a derivative, an analog, a hydrate, an ester, or a salt thereof. 20. The drug delivery system of claim 19, wherein said at least one active agent is of sirolimus, everolimus, zotarolimus or biolimus. 21. The drug delivery system of claim 18, wherein the macrolide immunosuppressive drug comprises one or more of rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin, 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin, 40-O-(6-Hydroxy)hexyl-rapamycin, 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin, 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin, 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolimus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof. 22. A drug delivery system comprising a. a substrate; andb. a coating on said substrate comprising a first layer comprising at least one polymer; a second layer comprising at least one active agent; and an outer layer comprising at least one polymer; wherein each of said polymer layers comprises a separately sintered polymer layer; wherein said outer layer comprising said at least one polymer is sufficiently thin so that the active agent is present in crystalline form on at least one region of an outer surface of the coating opposite the substrate and wherein between 25% and 50% of the total amount of active agent in the coating is released after 24 hours in vitro elution. 23. The drug delivery system of claim 22, wherein the polymer comprises is at least one of: a fluoropolymer, PVDF-HFP comprising vinylidene fluoride and hexafluoropropylene monomers, PC (phosphorylcholine), Polysulfone, polystyrene-b-isobutylene-b-styrene, PVP (polyvinylpyrrolidone), alkyl methacrylate, vinyl acetate, hydroxyalkyl methacrylate, and alkyl acrylate. 24. The drug delivery system of claim 23, wherein the alkyl methacrylate comprises at least one of methyl methacrylate, ethyl methacrylate, propyl methacrylate, butyl methacrylate, hexyl methacrylate, octyl methacrylate, dodecyl methacrylate, and lauryl methacrylate; and wherein the alkyl acrylate comprises at least one of methyl acrylate, ethyl acrylate, propyl acrylate, butyl acrylate, hexyl acrylate, octyl acrylate, dodecyl acrylates, and lauryl acrylate. 25. The drug delivery system of claim 22, wherein the polymer is not a polymer selected from: PBMA (poly n-butyl methacrylate), Parylene C, and polyethylene-co-vinyl acetate. 26. The drug delivery system of claim 22, wherein the polymer comprises a durable polymer. 27. The drug delivery system of claim 22, wherein the polymer comprises a bioabsorbable polymer. 28. The drug delivery system of claim 27, wherein the bioabsorbable polymer is selected from the group PLGA, PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e-caprolactone) PDO, poly(dioxolane) PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(1,3-bis-p-(carboxyphenoxy)propane-co-sebacic acid). 29. The drug delivery system of claim 22, wherein said at least one active agent is at least 50% crystalline. 30. The drug delivery system of claim 22, wherein said at least one active agent is at least 90% crystalline. 31. The drug delivery system of claim 22, wherein said substrate is formed of at least one of stainless steel material and a cobalt chromium alloy. 32. The drug delivery system of claim 22, wherein said substrate has a thickness of from about 50% to about 90% of a total thickness of the system. 33. The drug delivery system of claim 22, wherein said drug delivery system has a thickness of from about 20 μm to about 500 μm. 34. The drug delivery system of claim 22, wherein said substrate has a thickness of from about 50 μm to about 80 μm. 35. The drug delivery system of claim 22, wherein the coating has a total thickness of from about 5 μm to about 50 μm. 36. The drug delivery system of claim 22, wherein said drug delivery system has an active agent content of from about 5 μg to about 500 μg. 37. The drug delivery system of claim 22, wherein the outer layer comprising at least one polymer has a thickness of less than about 5 μm. 38. The drug delivery system of claim 22, wherein said at least one active agent comprises a macrolide immunosuppressive (limus) drug. 39. The drug delivery system of claim 38, wherein said at least one active agent is rapamycin, a prodrug, a derivative, an analog, a hydrate, an ester, or a salt thereof. 40. The drug delivery system of claim 38, wherein the macrolide immunosuppressive drug comprises one or more of rapamycin, biolimus (biolimus A9), 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4′-Hydroxymethyl)benzyl-rapamycin, 40-O-[4′-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3′-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2′-en-1′-yl]-rapamycin, (2′:E,4′S)-40-O-(4′,5′-Dihydroxypent-2′-en-1′-yl)-rapamycin, 40-O-(2-Hydroxy)ethoxycar-bonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin, 40-O-(6-Hydroxy)hexyl-rapamycin, 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin, 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin, 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin, 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N′-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin, 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2′-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4′,5′-Dicarboethoxy-1′,2′,3′-triazol-1′-yl)-ethyl]-rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)-rapamycin (zotarolimus), and salts, derivatives, isomers, racemates, diastereoisomers, prodrugs, hydrate, ester, or analogs thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (244)
Fenster, Aaron; Downey, Donal B., 3D ultrasound-guided intraoperative prostate brachytherapy.
Roby Mark S. (Killingworth CT) Bennett Steven L. (New Haven CT) Liu Cheng-Kung (Norwalk CT), Absorbable block copolymers and surgical articles fabricated therefrom.
Krezanoski Joseph Z. (Los Altos CA), Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery t.
Wang James C. (Norton) Roberts George R. (Arlington) Pederson ; Sr. Brian A. (So. Attleboro MA), Co-extruded medical balloons and catheter using such balloons.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L., Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent.
Liu Cheng-Kung (Norwalk CT) Jiang Ying (North Haven CT) Roby Mark S. (Killingworth CT) Bennett Steven L. (New Haven CT) Stevenson Richard P. (Colchester CT) Pietrangeli Jeffrey P. (Bridgeport CT), Composite bioabsorbable materials and surgical articles made therefrom.
Loscalzo, Joseph; Vita, Joseph A.; Loberg, Michael D.; Worcel, Manuel, Composition for treating vascular diseases characterized by nitric oxide insufficiency.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Appel, Leah E.; Curatolo, William J.; Herbig, Scott M.; Nightingale, James A. S.; Thombre, Avinash G., Controlled release by extrusion of solid amorphous dispersions of drugs.
Chandrashekar Bhagya L. ; Zhou Mingxing ; Jarr Eileen M. ; Dunn Richard L., Controlled release liquid delivery compositions with low initial drug burst.
Merida A. D'Augustine ; James H. Liu ; Donald C. Harrison, Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections.
Burke,Sandra E.; Cromack,Keith R.; Mack,Matthew; Toner,John L., Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens.
Hoy Kenneth L. (St. Albans WV) Nielsen Kenneth A. (Charleston WV), Electrostatic liquid spray application of coating with supercritical fluids as diluents and spraying from an orifice.
Palmaz, Julio C.; Boyle, Christopher T.; Banas, Christopher E.; Wiseman, Roger W.; Marton, Denes, Endoluminal implantable devices and method of making same.
Francis Moussy ; Donald Kreutzer ; Diane Burgess ; Jeffrey Koberstein ; Fotios Papadimitrakopoulos ; Samuel Huang, Implant coating for control of tissue/implant interactions.
Yoon Seok-Joon,KRX ; Yeo Guw-Dong,KRX ; Kim You-Chan,KRX ; Seo Min-Hyo,KRX ; Pai Chaul-Min,KRX ; Jung Jong-Pyoung,KRX ; Lee Seung-Jin,KRX, Implantable bioresorbable membrane and method for the preparation thereof.
McNaughton Allen D. (Mountain View CA) Albert Stephen B. (Redwood City CA) Furbershaw Gerard A. (Santa Clara CA), Implanting device and implant magazine.
Canham, Leigh T; Barrett, Christopher P; Cox, Timothy I; Wright, Peter J; Bowditch, Andrew P, Implants for administering substances and methods of producing implants.
Tice Thomas R. (Birmingham AL) Lewis Danny H. (Gardendale AL) Cowsar Donald R. (Birmingham AL) Beck Lee R. (Birmingham AL), Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents.
Fogarty Thomas J. (770 Welch Rd. Palo Alto CA 94305) Finn ; III James C. (Stanford CA) Kinney Thomas B. (Mountain View CA), Inverted balloon catheter having sealed through lumen.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Mistrater Alan B. (Rochester NY) Pietrzykowski ; Jr. Stanley J. (Rochester NY) Klein Alfred O. (Rochester NY) Hendrix Loren E. (Webster NY) Petropoulos Mark C. (Ontario NY) Batt Gary A. (Fairport NY), Mandrel with flared, dish shaped disk and process for using mandrel.
Shaw, Wendy J.; Yonker, Clement R.; Fulton, John L.; Tarasevich, Barbara J.; McClain, James B.; Taylor, Doug, Medical implants and methods of making medical implants.
Whitbourne, Richard J.; Chamberlain, Alexandra M.; Hullihen, Daniel G.; Rosebrough, Scott F.; Calistri-Yeh, Mildred, Medicated stent having multi-layer polymer coating.
Pletcher Timothy Allen ; Datta Pabitra ; Poux Christopher Just ; McCoy Randall Eugene, Method and apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate.
Burnham, Theodore A.; Cha, Sung W.; Walat, Robert H.; Kim, Roland Y.; Anderson, Jere R.; Stevenson, James F.; Suh, Nam P.; Pallaver, Matthew, Method and apparatus for microcellular polymer extrusion.
Lars Lidgren SE; Peter Bengtsson SE; Peter Sj{overscore (o)}vall SE; Bengt Wesslen SE, Method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof.
Luzzi Louis A. ; Needham Thomas E. ; Hossein Zia ; Dondeti Polireddy, Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa.
Anderson Jere R. (Newburyport MA) Jandris Louis J. (Georgetown MA) Barbere Michael D. (Dunstable MA) Murphy Richard T. (Dracut MA 4), Method of making a distensible dilatation balloon using a block copolymer.
McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L., Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia.
DeYoung, James P.; Gross, Stephen M.; Wagner, Mark I.; McClain, James B., Methods and compositions for etch cleaning microelectronic substrates in carbon dioxide.
Roser, Bruce J.; Sanderson, Ian; Kampinga, Jaap; Colaco, Camilo, Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery.
D'Amato, Robert J.; Green, Shawn J.; Swartz, Jr., Glenn M.; Shah, Jamshed H.; Madsen, John, Methods and compositions for treating an ocular neovascular disease.
DeYoung, James P.; McClain, James B.; Gross, Stephen M.; Wagner, Mark I., Methods for transferring supercritical fluids in microelectronic and other industrial processes.
Hossainy, Syed Faiyaz Ahmed; Tang, Yiwen; Askaryar, Homayon; Lin, Qing; Glauser, Thierry, Methods of forming coatings with a crystalline or partially crystalline drug for implantable medical devices.
Cha Sung W. (Cambridge MA) Suh Nam P. (Sudbury MA) Baldwin Daniel F. (Medford MA) Park Chul B. (Cambridge MA), Microcellular thermoplastic foamed with supercritical fluid.
Kent John S. (Cupertino CA) Lewis Danny H. (Birmingham AL) Sanders Lynda M. (Palo Alto CA) Tice Thomas R. (Birmingham AL), Microencapsulation of water soluble active polypeptides.
Tepper, Gary; Pestov, Dmitry; Levit, Natalia; Wnek, Gary, Molecular imprinting of small particles, and production of small particles from solid state reactants.
Beckert, Thomas; Petereit, Hans-Ulrich; Dressman, Jennifer; Rudolph, Markus, Multi-particulate form of medicament, comprising at least two differently coated forms of pellet.
Maxfield MacRae (Plainfield NJ) Christiani Brian R. (Maplewood NJ) Murthy Sanjeeva N. (Neshanic Station NJ) Tuller Harold (Long Valley NJ), Nanocomposites of gamma phase polymers containing inorganic particulate material.
Haslam John L. (Lawrence KS) Higuchi Takeru (Lawrence KS) Mlodozeniec Arthur R. (Lawrence KS), Ophthalmic drug delivery system utilizing thermosetting gels.
Cecchi, Roberto; Croci, Tiziano; Guzzi, Umberto; Marsault, Eric, Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same.
Raeder-Devens, Jennifer E.; Shelso, Susan I.; Hemerick, James F.; Schneider, Eric M.; Getty, Heather L.; Borgmann, Doreen M.; Sisombath, Kakao; Helgerson, Jeffrey A., Prosthesis deployment device with translucent distal end.
Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Osborne, Thomas A.; Ragheb, Anthony O.; Roberts, Joseph W.; Voorhees, III, William D., Silver implantable medical device.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Lafont Antoine,FRX ; Vert Michel R.,FRX ; Cornhill Fredrick ; Li Suming,FRX ; Garreau Henri L.,FRX, Stent having a programmed pattern of in vivo degradation.
Fulton, John L.; Deverman, George S.; Matson, Dean W.; Yonker, Clement R.; Taylor, C. Douglas; McClain, James B.; Crowley, Joseph M., System and method for enhanced electrostatic deposition and surface coatings.
Setterstrom Jean A. ; Van Hamont John E. ; Reid Robert H. ; Jacob Elliot ; Jeyanthi Ramasubbu ; Boedeker Edgar C. ; McQueen Charles E. ; Jarboe Daniel L. ; Cassels Frederick ; Brown William ; Thies C, Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix.
Tsukashima Ross (San Diego CA) Jordan Matthew (Los Angeles CA) Jung Gordon (San Diego CA), Tri-fold balloon for dilatation catheter and related method.
Rodrigues Jose,FRX ; Belmain Daniel,FRX ; Barlet Thierry,FRX, Triboelectric projector, installation for projecting coating product and process for controlling such a projector.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.